Shotlee LogoShotlee
Blog
Download on theApp Store
Get it onGoogle Play
Skip to main content
Jim Cramer: Eli Lilly's GLP-1 Pill Will 'Revolutionize Everything' - Featured image
Finance

Jim Cramer: Eli Lilly's GLP-1 Pill Will 'Revolutionize Everything'

Dr. Adrian Vale, MD
Reviewed by Dr. Adrian Vale, MDInternal Medicine · Board-Certified Obesity Medicine
·December 23, 2025·2 min read

Track Smart

Calculate active GLP-1 levels automatically with Shotlee.

Download →

Jim Cramer commented on Eli Lilly's GLP-1 pill, anticipating a revolutionary impact. He also assessed other portfolio holdings, including Taiwan Semi, Chevron, SL Green, and Microsoft, providing insights into their respective sectors.

Share

Jim Cramer on Eli Lilly's GLP-1 Pill

Jim Cramer offered insights on Eli Lilly and Company (NYSE:LLY) when responding to questions about portfolio diversification. The caller noted their top five holdings included LLY, SLG, MSFT, CVX, and TSM.

Cramer stated, "Really interesting setup here. Okay, so, Taiwan Semi is the actual fab that makes the chips for Broadcom, makes chips for AMD, makes chips for, yes, NVIDIA. Alright, that's in Taiwan. Very important. Eli Lilly is the company that has GLP-1 Mounjaro, very powerful drug. They're going to have a pill form next year that's going to revolutionize everything. I think the stock's going up another $500 billion, I kid you not. Chevron is my favorite large oil company with a good yield. That's run by Mike Wirth. SL Green is a company that's come back from the dead basically, and it's a REIT... in New York. I'm not really, I don't really want a REIT in New York, but that's what they do. And then Microsoft, okay, Mr. Softee, we know it's business-to-business software with the consumer side of it too. So I'm going to say, this is semi, this is software, this is drug, this is oil, and this is retail, and I'm going to bless all of them. Now, would I keep SL Green? I do happen to see Federal Realty coming back, and I'd like to see Don Wood in that portfolio instead of SL Green."

Precision tracking for your journey

Join thousands using Shotlee to accurately track GLP-1 medications and side effects.

📱 Get the Shotlee App

Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!

Download on theApp Store
Get it onGoogle Play

Eli Lilly and Company (NYSE:LLY) focuses on the development and marketing of medications for various conditions, including diabetes, obesity, oncology, immunology, and neuroscience, among other chronic diseases. Health tracking apps like Shotlee can help monitor health data relevant to these conditions.

Cramer's analysis provided a comprehensive overview of the caller's investment choices, highlighting the potential of Eli Lilly's pharmaceutical advancements and the importance of diversification across different sectors.

Source Information

Originally published by Yahoo! Finance.Read the original article →

Read next

Keep exploring

More in Finance

Retatrutide: The Next Frontier in Weight Loss and Its Profound Implications
Health & Wellness

Retatrutide: The Next Frontier in Weight Loss and Its Profound Implications

Eli Lilly's experimental drug retatrutide is showing unprecedented weight loss results, pushing the boundaries of what's possible. But with great power comes great responsibility, and doctors are urging caution.

7 min read
Beyond Ozempic: The Future of Weight Loss & Metabolic Health Innovation
Health & Wellness

Beyond Ozempic: The Future of Weight Loss & Metabolic Health Innovation

The GLP-1 revolution is just the beginning. This article delves into the cutting-edge advancements poised to reshape the future of weight loss and metabolic health, offering insights for patients and observers alike.

7 min read
Beyond Weight Loss: The Next Wave of GLP-1 Drugs
Health & Wellness

Beyond Weight Loss: The Next Wave of GLP-1 Drugs

The revolutionary GLP-1 medications have transformed weight management, but the journey of innovation continues. Discover how upcoming drugs aim to enhance patient experience and outcomes.

7 min read
Share this article
  1. Home
  2. Blog
  3. Jim Cramer: Eli Lilly's GLP-1 Pill Will 'Revolutionize Everything'
Dr. Adrian Vale, MD — Internal Medicine · Board-Certified Obesity Medicine
Medically reviewed

Dr. Adrian Vale, MD

Internal Medicine · Board-Certified Obesity Medicine

Dr. Adrian Vale is a board-certified internal medicine physician with a clinical focus on obesity medicine and metabolic health. He reviews Shotlee guides and articles on GLP-1 medications, peptide therapy, and weight-management protocols for clinical accuracy.

View all articles reviewed by Dr. Adrian Vale, MD
Shotlee LogoShotlee

Your comprehensive health tracking companion. Track, analyze, and optimize your journey with advanced metrics and community support.

Product

  • Medication Trackers
  • Health Guides
  • Calculators
  • Compare Medications
  • Pricing

Resources

  • Health Blog
  • Support Center

Legal

  • Privacy Policy
  • Terms of Service
  • Community Guidelines
  • Refund Policy

© 2026 Shotlee. All rights reserved.

Made with for the community♥ for the community